The prognosis of dengue remains a challenge in the early, objective triage of patients with dengue fever of differing severity. Circulating immuno-modulating proteins have brought new possibilities as prognostic markers of severe dengue (SD). This systematic review is devoted to understanding the potential utility of blood-based cytokines and chemokines as prognostication markers of SD based on the current literature. PubMed and Embase were searched. Of 794 candidate articles, 685 abstracts were screened against our exclusion/inclusion criteria and 25 (3.6 %) studies met the quality assessments. A total of 18 studies were retrospective observational and 2 were prospective cohort studies. Elevated IL-10, up to day 7 of fever onset, stood out as a candidate prognostic marker for SD using the 1997 and 2009 World Health Organization (WHO) case definitions. IFNg was another potential prognostic marker of SD (1997 WHO case definition), but its levels varied between studies. Significant heterogeneity in methodologies and patient cohorts prevent ready application of IL-10 and IFNg as prognostic markers to other dengue populations. Our results suggest that the current non-randomized studies are delivering inconsistent messages and higher-quality studies, with consistent methodologies and validation in independent patient cohorts, are needed to delineate confounding variables. Major gaps identified were full accounting and transparency of sampling days, dengue virus type, infection status and age group.
Introduction
Dengue is an emerging arboviral threat globally as its spread and incidence is moving on an upward trajectory, infecting some 390 million people yearly (Bhatt et al., 2013) . Dengue can be asymptomatic, or present as a self-limiting dengue fever (DF), and in certain patient subsets the disease may precipitate into the severe, potentially life-threatening forms of dengue -dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) or severe dengue (SD). In the 1997 World Health Organization (WHO) case definition, patients were diagnosed as having DHF if they had fever, thrombocytopenia, bleeding and evidence of plasma leakage (hypoproteinaemia, change in haematocrit of more than 20 % or clinical fluid accumulation) (WHO, 1997) . DSS has all the features of DHF plus circulatory failure in the form of rapid and weak pulse, and narrow pulse pressure (<20 mm Hg), or agespecific hypotension and cold, clammy skin and restlessness. In the 2009 WHO case definition, patients were diagnosed as SD if they had severe plasma leakage, severe bleeding and severe organ involvement (aspartate aminotransferase or alanine aminotransferase!1000 U/L, impaired consciousness, or failure of heart and other organs) (WHO, 2009) . Dengue can be caused by any of the four dengue types of the genus Flavivirus. The propensity to develop SD is plausibly brought about by a number of factors, including heterologous secondary dengue infection, dengue type, age or a combination of these (Kyle & Harris, 2008; OhAinle et al., 2011) . There are no effective antiviral therapeutics to treat dengue and the current most advanced vaccine has an imbalanced efficacy against the four dengue types (Capeding et al., 2014; Wilder-Smith & Massad, 2016) . In view of this, early prognosis of SD, preferably less than 96 h from onset of fever, can guide patient triage, allow informed clinical decisions, and reduce disease morbidity and mortality.
The dynamic nature of dengue presents significant challenges in clinical management and on health services, especially during an outbreak. Currently, routine haematological and biochemical measurements in dengue patients collectively correlate poorly with eventual clinical outcome, there are no tests to differentiate those who will have DF from those who will progress to and deteriorate to SD. In the absence of any effective treatment against the disease, proper fluid management is critical. Guidelines produced by the WHO list a number of warning signs to help inform clinical decision making, but they all have poor specificity resulting in large numbers being admitted unnecessarily . Over-hospitalization of dengue patients is contributed to in part by the inability to prognosticate early in the febrile phase, and resulted in excessive hospitalization rates and costs . The unpredictable nature of outbreaks often overwhelms already fragile health-care systems. Prognosis is also important for monitoring dengue patients who display probable warning signs of health deterioration or complications that warrant further investigation. A prognostic marker is defined as a clinical or biological characteristic that is objectively measurable and that provides information on the likely outcome of the disease in an untreated individual (Hayes et al., 1998) .
Faced with the limited utility of current methods of SD prognosis, there has been interest in investigating the utility of systemic soluble factors as potential markers of SD prognosis. The two main prevailing hypotheses of DHF/DSS pathogenesis, antibody-dependent enhancement (ADE) and original antigenic sin (or T cell immunopathology), centre on an imbalanced immune system during secondary dengue infection (Halstead & O'Rourke, 1977; Mongkolsapaya et al., 2003) triggering an exaggerated and imbalanced inflammatory cascade (Srikiatkhachorn & Green, 2010) . In addition to secondary infections, the waning maternally-derived anti-dengue virus (DENV) IgG antibodies and/or an altered cytokine profile may explain SD in infants with primary infections (Libraty et al., 2009; Nguyen et al., 2004) . Soluble factors emanating from immune cells (T cells, B cells, macrophages, mast cells, dendritic cells, etc.) , platelets, stromal and endothelial cells in the form of cytokines and chemokines act as signalling molecules synergizing with one another to orchestrate cell growth and proliferation, differentiation/maturation, and immunity; hence, modulating host responses to infections (Fink et al., 2006) . Cytokines and chemokines are small proteins typically ranging from 8 to 40 kDa, and in this review we broadly refer to them as immuno-modulating proteins. Cytokines are secreted proteins that play a role in cell signalling, in the induction, inhibition and effector phases of immune and inflammatory responses. Chemokines are a subset of small cytokines that recruit and exert chemotactic migration of other cells to a localized area to exert a variety of biological effects, including inflammation and homeostasis. Immunomodulating protein profiles change with the clinical course of dengue, differ between DF and SD Rathakrishnan et al., 2012) , and are believed to have direct impact on the manifestations of increased vascular permeability, plasma leakage and thrombocytopenia (Green & Rothman, 2006; Murphy & Whitehead, 2011) . Immunomodulating proteins have been proposed to cause a shift from the predominant TH 1 -type response in DF to the TH 2 -type in severe DHF (Fink et al., 2006) ; because molecular signalling seemingly precedes gross morphological or observable clinical symptoms, the potential use of immuno-modulating proteins as early prognostic markers is especially welcoming . However, studies in humans have resulted in varied responses and remained conflicting, with no objective consolidation of data having taken place so far. Hence, this systematic review aims to be a collection and summary of primary research articles that focuses on the ostensible utility of soluble immuno-modulating markers for the prognosis of SD.
Results

Study selection
We ran searches on PubMed and Embase, and a total of 794 references were retrieved: PubMed (n=451) and Embase (n=343). After excluding 109 duplicates, 685 records were screened on the basis of title and abstract against our exclusion/inclusion criteria, thereby identifying 54 potentially eligible records (Table S1 , available in the online Supplementary Material). Two studies were excluded because the main text could not be retrieved or had incomplete methods. Another 30 records were excluded (4 low quality, 25 medium quality and 1with ambiguous sampling time). Some of the studies were further moderated based on empirical evidence leading to six studies being downgraded and one study being upgraded (Table S1 ). A total of 24 studies were identified as eventual eligible articles of high quality. The study selection flow chart is shown in Fig. 1 . We restricted the search to 'English' language and 'Human' subjects. Three studies were excluded despite good study design due to a lack of comparison to DHF/DSS or SD (medium to high quality). Detection bias (blinding of outcome assessors) was relatively homogeneous across these non-randomized studies (NRS) and leaves all studies at approximately the same level of risk of bias and, thus, not considered.
Study characteristics
A total of 19 out of 24 studies were case-control studies (Arias et al., 2014; Bozza et al., 2008; Brasier et al., 2012; Butthep et al., 2012; Chen et al., 2005; Furuta et al., 2012; Green et al., 1999a, b; Guerrero et al., 2013; Houghton-Triviño et al., 2010; De La Cruz Hern andez et al., 2014; Laur et al., 1998; Levy et al., 2010; Malavige et al., 2013a; Nguyen et al., 2004; Del Moral-Hern andez et al., 2014; P erez et al., 2004; Soundravally et al., 2014; Wang et al., 2007) , and the remaining 5 studies were prospective cohort studies (de-Oliveira-Pinto et al., 2012; Kurane et al., 1991 Kurane et al., , 1993 Suharti et al., 2003) . Comparison groups were healthy controls, patients with other febrile illness (OFI) or non-severe disease patients (DF or non-SD); however, comparisons made between SD and non-SD cases were considered most ideal for the purpose of this review. Study characteristics of the 24 studies are reported in Table 1 . One study did not specify which WHO case definition was applied, but this was verified with the authors and the manuscript was subsequently accepted for further evaluation (de-Oliveira-Pinto et al., 2012) .
Ten studies noted affirmatively that their first blood sampling was performed at the febrile phase, which we defined here as <5 days or <96 h from fever onset (Brasier et al., 2012; Butthep et al., 2012; Green et al., 1999a, b; De La Cruz Hern andez et al., 2014; Malavige et al., 2013a; P erez et al., 2004; Soundravally et al., 2014; Wang et al., 2007) . The remaining studies had wider blood sampling windows, ranging from 1 to 10 days from symptom onset (Arias et al., 2014; Bozza et al., 2008; Chen et al., 2005; de-Oliveira-Pinto et al., 2012; Guerrero et al., 2013; Houghton-Triviño et al., 2010; Kurane et al., 1991 Kurane et al., , 1993 Laur et al., 1998; Levy et al., 2010; Del Moral-Hern andez et al., 2014; Nguyen et al., 2004; Suharti et al., 2003) . A majority of studies (21/24, 87.5 %) employed ELISAs for quantification of single cytokine/chemokine, or multiplexed suspension bead immunoassays for broader profiling. Three studies (12.5 %) used cytometric bead arrays (Guerrero et al., 2013; Houghton-Triviño et al., 2010; De La Cruz Hern andez et al., 2014) .
Assessment of study design eligibility and risk of bias in individual studies Table S2 summarizes the risk of study design eligibility and bias of selected studies according to the Cochrane NRS Methods group. First, all studies compared DHF, DSS or SD with DF, dengue without warning signs (DwoWS) or dengue with warning signs (DwWS) groups, as this was part of our quality assessment criterion (Table 2) . Therefore, risk of bias in this item was negative. We considered the risk related to retrospective design as moderate, because the outcome assessments were retrospective and the generation of the hypothesis was prospective. Detection risk was considered low because patients were categorized according to canonical and accepted definitions of dengue severity clinical symptoms (WHO, 1997 (WHO, , 2009 and not by patients' preference or marker (assay) outcomes. One study applied modified WHO guidelines (Bozza et al., 2008) . However, Cytokines and chemokines as dengue prognosis biomarkers (2) higher mean plasma IL-12 (p40+p70) DHF compared to DF from fever day À2 (2) a convalescent specimen was collected from each child 7-10 days after hospital admission WHO (1986) (1) Increased IFNa in DHF than in controls on days 2-4, days 6-7 and days 10-20; (2) increased IFNa in DF than in controls on day 1 and day 3, but levels were not high on day 4-20 after onset of fever;
(3) mean levels of IFNa in DHF patients were highest 2 days before deferevescence, and decreased gradually until day of defervescence, IFNa levels did not change during day 0-19; (4) IFNa levels in DF patients were high 1 day before and on the day of defervescence, but these levels were not high after fever subsided; (Table 1) . Studies differed in the types of immuno-modulating proteins investigated, and the most frequently profiled cytokines and chemokines were TNFa (12/20, 60 %), IFNg (11/20, 55 %), IL-6 (10/20, 50 %), IL-10 (9/20, 45 %), IL-4 (6/20, 30 %) and IFNa (3/20, 15 %). Despite being the most investigated cytokine, TNFa was significantly elevated in DHF patients in only five studies (Houghton-Triviño et al., 2010; Levy et al., 2010; Nguyen et al., 2004; Soundravally et al., 2014; Wang et al., 2007) , and one study found no statistical difference in TNFa levels between DF and DHF patients (Laur et al., 1998) . The rest of studies reported no statistical difference or did not detect TNFa. By contrast, IL-10 stood out as the cytokine for which concentration was elevated in DHF relative to DF patients consistently in seven studies utilizing the WHO (1986)/WHO (1997) case definition (Table 3 ) (Brasier et al., 2012; Butthep et al., 2012; Chen et al., 2005; Green et al., 1999b; Houghton-Triviño et al., 2010; Nguyen et al., 2004; P erez et al., 2004) . The association of dengue severity with circulating levels of IFNg was more heterogeneous (Table 4 ) (Bozza et al., 2008; Butthep et al., 2012; Chen et al., 2005; Nguyen et al., 2004; Soundravally et al., 2014) . Three studies noted increased IFNg in DHF and/or DSS patients relative to DF patients or healthy controls (Bozza et al., 2008; Butthep et al., 2012; Nguyen et al., 2004) , whereas three studies noted decreased IFNg levels in DHF/DSS over DF patients (Chen et al., 2005; Soundravally et al., 2014) . Bozza et al. (2008) noted defervescence phase IFNg levels in adults (age 15-73 years) were associated with disease severity (odds ratio=1.138, 95 %confidence interval1.041 to 1.245, P=0.0046). However, Green et al. (1999a) reported no significant difference in febrile IFNg between DF and DHF paediatric patients. In congruence, in infants (age <1 year), IFNg (together with IL-2, IL-4, IL-6, IL-10, TNFa)
could not differentiate DHF I/II from DHF III/IV (Nguyen et al., 2004) .
Prognostication marker candidates: WHO (1997) DHF III/IV
One study looked specifically at immuno-modulatory markers of predicting DSS (DHF III/IV) mortality (Suharti et al., 2003) . The study population was restricted to only DENV3-infected paediatric patients who were diagnosed as DSS in a prospective study. In the acute phase of dengue infection, plasma IL-1Ra levels were significantly higher in DSS non-survivors (n=7) compared to DSS survivors (n=43; 802.2±566.4 vs 1566.9±675.6 pg ml À1 , P=0.0005). Multiple logistic regression identified IL-1Ra as having significant association with mortality on the day of admission (P=0.007).
Prognostication marker candidates: WHO (2009) SD
Of the selected 24 studies, 4 studies (16.7 %) employed the WHO (2009) case definition (Arias et al., 2014; de-OliveiraPinto et al., 2012; Guerrero et al., 2013; Malavige et al., 2013a) . Among them, one reported elevation in IL-10 (Malavige et al., 2013a), congruent with the seven WHO (1997) guideline-utilizing studies that reported elevations in IL-10 in DHF patients (Table 3) , and one study reported elevated IL-10 levels in DwoWS, DwWS and SD patients compared to controls (Guerrero et al., 2013) . Two studies reported elevations in sST2 (IL-1RL1) (Arias et al., 2014; Guerrero et al., 2013) in SD patients in levels above those of DwoWS and DwWS (Arias et al., 2014; Guerrero et al., 2013) . The same studies reported increased IL-6 levels in SD and DwWS relative to patients with DwoWS. Elevations in TNFRI and TNRFII in DwoWS, DwWS and SD (Arias et al., 2014) were similar to those observed in DHF patients (Wang et al., 2007) .
Discussion
Our systematic review of studies published from 1998 to 2014 evaluated cytokines and chemokines as potential early markers to prognosticate the development of SD. We evaluated and documented judgements about evidence quality from NRS and incorporated this into reporting of differentially changed cytokines and/or chemokines for outcomes based on WHO (1986)/WHO (1997) or WHO (2009) dengue case definitions. Twenty-four studies were identified to be of suitably high quality, but with major gaps in descriptions of patient demographics, DENV types and infection status (primary, secondary or tertiary infections). Although a consensus has yet to emerge, IL-10 levels stood out as a potential marker of SD (DHF and SD) that was significantly increased regardless of age (range 1 month to 76 years) or infection status (primary or secondary).
Eight studies utilizing WHO (1986 )/WHO (1997 or WHO (2009) case definitions demonstrated elevated IL-10 levels in SD patients. Interestingly, several studies, including a recent publication, showed similar IL-10 levels between patients with and without SD (Bozza et al., 2008; Cui et al., 2016; Guerrero et al., 2013; . The reason for this discrepancy is not entirely clear. IL-10 is an important anti-inflammatory cytokine and general suppressor of immune reactions, inhibiting IL-1, IL-6, IL-10 itself, IL-12, IL-18, CSF and TNFa, as well as inhibiting the synthesis of IL-2, IL-3, GM-CSF, TNFa and IFN-g (D' Andrea et al., 1993) . IL-10 may contribute to disease severity through NS1-induced IL-10 production by monocytes, which in turn suppresses dengue-specific T cell responses (Adikari et al., 2016; Malavige et al., 2013b) . Notably, data from animal studies suggest that NS1 activates immunological cascades in monocytes and macrophages leading to the pathologies observed in SD (Chen et al., 2015; Modhiran et al., 2015) . In addition to its immunosuppressive roles, IL-10 has recently been reported as a protective mediator against plasma leakage and vascular dysfunction (Cheng & Sharma, 2015) . IL-10 is secreted by a variety of cell types including CD4 + and CD8 + T cells, B cells, macrophages, monocytes, eosinophils and mast cells (O'Garra & Vieira, 2007) . Measurements of circulating levels of IL-10 reflect the sum total of IL-10 produced from all cells in the body at any one point. Production of IL-10 may change according to the predominant cell type specific to the day of infection to regulate viral clearance immunopathology (reviewed by Tsai et al., 2013b) as different immune cells are invoked at different stages of dengue infections (Boonnak et al., 2008; Clyde et al., 2006) . The timing of IL-10 production is dynamic and varies throughout the disease course, exemplified by IL-10 levels peaking around early defervescence in DHF patients, but less so in DF patients (Adikari et al., 2016; Butthep et al., 2012; Libraty et al., 2002a) , suggesting that the biggest difference between DF and DHF patients may be observed around the day of early defervescence. Mechanistically, the intrinsic ADE of DENV infections may modulate the severity of dengue via increased IL-10 production and subsequent enhancement of the Suppressor of Cytokine Signalling (SOCS) system (Chareonsirisuthigul et al., 2007; Suhrbier & La Linn, 2003; Ubol et al., 2010) . Furthermore, in vitro studies suggest that in ADE-DENV infections, the role of IL-10 changes in the early and later stages of infection from anti-viral to immunoregulation (Halstead et al., 2010; Tsai et al., 2013b) . Two studies noted significant elevations in IL-10 and IFNg in DHF and DSS patients compared to DF patients (P<0.01) (Butthep et al., 2012; Nguyen et al., 2004) , whereas one study showed elevated IL-10 levels (DF 11.7±3.5 vs DHF 117.0±52.8 pg ml
À1
; P=0.03) but decreased IFNg in DHF compared to DF (DF 130.2±16.9 vs DHF 84.2±12.6 pg ml À1 ; P=0.01) (Chen et al., 2005) . By contrast, three other studies reported increased IL-10 levels in DHF patients, but no difference in IFNg between DF and DHF patients (Brasier et al., 2012; Green et al., 1999a; Houghton-Triviño et al., 2010) . Note that these studies had different sampling timings. In addition, we found no consistent trend of any potential interactions between IL-10 with the following cytokines: IL-2, IL-6, IL-12 and TNFa. This is congruent with other studies as cytokine changes are often mixed in dengue infections in different populations (Chaturvedi et al., 2000) , with the exception of IL-10 as it is shown in this systematic review. Collectively, the exact sampling timing of IL-10 may be a critical aspect in determining its maximal potential as a marker for SD prognosis.
The discrepancy of IFNg in the five studies could be due to the rapid kinetics in its circulating levels, and depending on which infection day blood was sampled and analysed the IFNg levels could be different (Green et al., 1999a; Libraty et al., 2002b; Nguyen et al., 2004) . Reports from humans and from animal models suggest that IFNg controls infections through viral clearance and limiting virus replication (Costa et al., 2012; Horras et al., 2011; Pal et al., 2014; Shresta et al., 2004) . Notably, dengue viral titres correlate with disease severity (Endy et al., 2004; Vaughn et al., 2000) , but are plausibly influenced by DENV type and infection status (Duyen et al., 2011) . Levels of IFNg can be attenuated by IL-10 through SOCS-3 blockage of STAT1-IFNg receptor interaction in intrinsic ADE-DENV infection (Chareonsirisuthigul et al., 2007; Ubol et al., 2010) . Indeed, the absence of IFNg in a mouse model of dengue led to primary dengue-infection-induced lethality (Costa et al., 2012) . Thus, depending on the infection status and DENV type, in combination with timing of IL-10 production, IFNg levels may be affected, leading to altered viral clearance, prolonged infection and consequently determining disease severity. IFNg levels peak before defervescence in DHF patients and peak after defervescence in DF patients, because of this the maximum difference in the febrile phase of dengue suggests an advantage of using IFNg as an early marker of SD. However, the implication and utility of IFNg needs further study with properly defined sampling windows and DENV types taken into consideration.
To our knowledge, this is the first systematic review of immuno-modulating proteins as prognostic markers of SD sequelae. Two earlier published reviews did not apply and justify quality assessments (Chaturvedi et al., 2000; Yacoub & Wills, 2014) . This is worth highlighting as the restriction of studies according to a set of inclusion/exclusion criteria, and the introduction of quality assessments, retained studies with better-defined methodologies. Longitudinal studies, where daily measurements of studied immuno-modulating proteins are taken, may best capture the dynamic kinetics of these proteins in dengue. Although a few immuno-modulating proteins are potentially promising as prognostic markers, prospective observation cohort trials, such as the one by International Research Consortium on Dengue Risk Assessment, Management, and Surveillance (IDAMS; https://ClinicalTrials.gov; identifier: NCT01550016), may aid further endorsement of the utility of an acute phase prognostic marker for SD. In addition, immuno-modulating proteins, in reflecting the cardinal symptoms of SD, plasma leakage and thrombocytopenia, should be given research priority (Yacoub & Wills, 2014; Zapata et al., 2014) . One promising example is TNFa, which was reported to induce endothelial cell apoptosis and was also noted in this review as an elevated IP: 54.70.40.11
On: Sun, 30 Jun 2019 05:05:34 cytokine in DHF. Other potential circulating markers of dengue severity, such as proteases (Koraka et al., 2010; St John et al., 2013; van de Weg et al., 2014) , soluble adhesion molecules (Cardier et al., 2006) or metabolites (Cui et al., 2013 (Cui et al., , 2016 , may show potential as alternative soluble prognostic markers of SD, but face similar challenges in the extensive demands of large study cohorts. Capturing soluble factors that correlate and potentially foretell pathognomonic symptoms may not only increase the specificity and sensitivity of prognosing SD, but also avoid the non-specific 'cytokine storms' observed in other acute infectious diseases, such as influenza and malaria (Clark, 2007) .
There were several limitations in our review process. First, there were inadequate reports on the details of patient demographics, DENV type and patients' infection status (primary, secondary or tertiary infection) in the studies. Inclusion of such information may be necessary to understand why results may be heterogeneous. Critically, sampling windows (days of illness from onset of fever) were at times not documented, or varied widely, sometimes even within the same study. Second, endpoint measurements of these studies varied substantially, differing in the types of immuno-modulating proteins under study. Not all studies investigated the same type of immunomodulating proteins in relation to dengue severity. Furthermore, data presented in tables or figures in the published manuscripts rarely report concentration means and/or the range of the significantly different immuno-modulating proteins. This severely limited any statistical estimation of odds ratios, sensitivity and specificity of the prognosis marker candidates and prevents meta-analysis. Such wide variability in studies has been reported elsewhere (Potts & Rothman, 2008) . Third, after strictly adhering to internal assessments of the quality of the primary studies, further moderation led to six studies being downgraded and one study being upgraded (Table S1) . A study may have scored as high quality but may have been weighed down due to an unlisted criterion, for example, large variation in the studied cytokines (Chen et al., 2006) . Although this could potentially introduce bias, we included this empirical exercise to ensure retention or exclusion of studies that were under-or over-ranked but still added value to the review.
Conclusions
This systematic review provides the basis for future high-quality studies urgently required to identify key prognostic immuno-modulating protein markers of SD. They should be performed according to REMARK criteria (McShane et al., 2005) to avoid the methodological deficiencies discovered in this systematic review, mostly with substantial heterogeneity in the study populations and prognostic endpoints. Studies in larger population sizes should reflect in detail the study population's age, infection status and DENV types, with standardization on first sample collection timing (<96 h from fever onset), detailed patient infection information and prognostic endpoint measurements.
The use of soluble immuno-modulating proteins as prognostic markers of SD remains under investigation and yet a consensus marker or marker signature for prognosing SD is desirable. Is this achievable? Current evidence suggests that different patient subpopulations -age groups (adults vs children vs geriatric), DENV types 1 to 4, and infection statusrespond differently to dengue infections (Hammond et al., 2005; OhAinle et al., 2011; Tricou et al., 2011) . Accordingly, different markers may be needed to optimally prognose SD in different patient subpopulations , and potentially aid the design of dengue vaccines.
Methods
Search strategy and data extraction
The primary literature search was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews *The information provided here is a subset of patients described in Kalayanarooj et al. (1997) . and Meta-Analyses) guidelines (Moher et al., 2009) , via PubMed and Embase databases, for original research articles with restriction to human studies and English language. The search terms used for both databases were as followed: 'dengue AND (Cytokine OR Chemokine) AND (predict* OR prognos* OR correlat* OR associat* OR indicat*)'. We designed search strategies as shown in Table 5 . Table S3 . Assessment of outcome was not masked in all studies due to the need to diagnose dengue severity.
Subsequently, the quality of selected studies was assessed across a matrix of ten metrics, namely (i) study design, (ii) time of sampling, (iii) age, (iv) data collection, (v) diagnostic criteria, (vi) inclusion/exclusion criteria, (vii) infection status, (viii) DENV type, (ix) statistical analysis, (x) data statistics. The quality assessment score system was based on a modified version of the Newcastle-Ottawa scale (NOS) (Wells et al., 2013) and is described in Table 2 . The maximum score is 12, and a score of 9-12 is considered as high quality, 5-8 as moderate quality and 1-4 as low quality. The measure of agreement between the two reviewers (W. Y. L. and Y. H. L.) was assessed using the Kappa index (MedCalc version 12.5).
None of the studies were randomized clinical trials and because the studies were observational studies (case-control, cohort), we assessed the quality of evidence using a list of ten criteria modified from the NOS (Table 2) , rather than Grading of Recommendations, Assessment, Development and Evaluations (GRADE) (Guyatt et al., 2008) .
Ascertainment of outcomes relied on WHO (1986) , WHO (1997) or WHO (2009) dengue case definition guidelines. The WHO (1986) and WHO (1997) case definition guidelines were grouped together during analysis, but were analysed separately from the WHO (2009) case definition guidelines due to reported differences Narvaez et al., 2011; Tsai et al., 2013a Odds ratios or statistical mean/median values could not be identified in most studies. No pooling was done given the extra sources of methodological diversity (types of prognostic factors being measured) and bias. Hence, NRS are expected to be more heterogeneous than randomized trials.
